Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide extension in obese subjects
NCT00189514Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2005
- Primary completion
- Jun 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pramlintide in obesity (4 arms), sponsored by AstraZeneca. Primary endpoints: Body weight, Safety and 1 more. Started Sep 2005; status: completed.
02
Drugs
pramlintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00189514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189514.